Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Acquisitions (2010 - 2018)

Harvard Bioscience (HBIO) reported Acquisitions of $540000.0 for Q4 2018, down 9.24% on a QoQ basis from $595000.0 in Q2 2018.

Harvard Bioscience (HBIO) has 6 years of Acquisitions data on file, last reported at $540000.0 in Q4 2018.

  • Quarterly Acquisitions changed N/A year-over-year to $540000.0 in Q4 2018, while the trailing twelve-month figure through Sep 2019 was $540000.0 (down 99.21% YoY) and the FY2018 annual result came in at $68.5 million, changed N/A from the prior year.
  • Acquisitions declined to $540000.0 in Q4 2018 per HBIO's latest filing, from $595000.0 in the prior quarter.
  • Across five years, Acquisitions topped out at $67.4 million in Q1 2018 and bottomed at $540000.0 in Q4 2018.
  • The 3-year median for Acquisitions is $4.5 million (2015), against an average of $17.1 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn 528.20 Mn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn -
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn 24.88 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn -
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn -
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn -
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn 18.96 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn -
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn -
10 Harvard Bioscience 25.38 Mn 18.29 Mn 12.24 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 540,000.00
Jun 30, 2018 595,000.00
Mar 31, 2018 67.41 Mn
Mar 31, 2015 4.55 Mn
Dec 31, 2014 12.65 Mn
Dec 31, 2012 15,000.00
Jun 30, 2012 485,000.00
Mar 31, 2012 2.38 Mn
Dec 31, 2011 300,000.00
Sep 30, 2011 5.17 Mn
Dec 31, 2010 1.00 Mn
Sep 30, 2010 4.63 Mn